doi: 10.1097/HEP.0000000000000706.
Epub 2023 Dec 19.
From NAFLD to MASLD: Promise and pitfalls of a new definition †
Affiliations
- PMID: 38112428
- DOI: 10.1097/HEP.0000000000000706
Item in Clipboard
From NAFLD to MASLD: Promise and pitfalls of a new definition †
Hepatology.
.
No abstract available
Similar articles
-
Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' †.Hepatology. 2024 Feb 1;79(2):E16-E17. doi: 10.1097/HEP.0000000000000705. Epub 2023 Dec 19. Hepatology. 2024. PMID: 38112434 No abstract available.
-
Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition'.Ann Hepatol. 2024 Jul-Aug;29(4):101178. doi: 10.1016/j.aohep.2023.101178. Epub 2023 Dec 19. Ann Hepatol. 2024. PMID: 38944461 No abstract available.
-
Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease.J Hepatol. 2024 Jul;81(1):e20-e21. doi: 10.1016/j.jhep.2023.10.008. Epub 2023 Dec 19. J Hepatol. 2024. PMID: 38906627 No abstract available.
-
[Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].Rev Med Interne. 2024 Jan;45(1):41-47. doi: 10.1016/j.revmed.2023.10.438. Epub 2023 Dec 29. Rev Med Interne. 2024. PMID: 38158295 Review. French.
-
Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.Curr Gastroenterol Rep. 2023 Oct;25(10):213-224. doi: 10.1007/s11894-023-00883-8. Epub 2023 Sep 28. Curr Gastroenterol Rep. 2023. PMID: 37768417 Review.
Cited by
-
Interplay of Cardiometabolic Syndrome and Biliary Tract Cancer: A Comprehensive Analysis with Gender-Specific Insights.Cancers (Basel). 2024 Oct 9;16(19):3432. doi: 10.3390/cancers16193432. Cancers (Basel). 2024. PMID: 39410050 Free PMC article. Review.
-
Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control study.Cardiovasc Diabetol. 2024 Oct 17;23(1):367. doi: 10.1186/s12933-024-02461-2. Cardiovasc Diabetol. 2024. PMID: 39420429 Free PMC article.
-
Envisioning how to advance the MASH field.Nat Rev Gastroenterol Hepatol. 2024 Oct;21(10):726-738. doi: 10.1038/s41575-024-00938-9. Epub 2024 Jun 4. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38834817 Review.
-
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.Front Cell Dev Biol. 2024 Jul 16;12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39086662 Free PMC article. Review.
-
The Cardiac-Kidney-Liver (CKL) syndrome: the "real entity" of type 2 diabetes mellitus.Arch Med Sci. 2024 Jan 31;20(1):207-215. doi: 10.5114/aoms/183070. eCollection 2024. Arch Med Sci. 2024. PMID: 38414467 Free PMC article. No abstract available.
References
-
- Younossi ZM, Paik JM, Al Shabeeb R, Golabi P, Younossi I, Henry L. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology. 2022;76:1423–1437.
-
- Ciardullo S, Carbone M, Invernizzi P, Perseghin G, et al. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023;43:2425–2433.
-
- Song SJ, Lai JC, Wong GL, Wong VW, Yip TC, et al. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2023;S0168-8278:05000–05006.
-
- Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care. 2005;28:1769–1778.
-
- Simmons RK, Alberti KGMM, Gale EAM, Colagiuri S, Tuomilehto J, Qiao Q, et al. The metabolic syndrome: Useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia. 2010;53:600–605.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
